SLC5A2 and type 2 diabetes mellitus: Terms included “type 2 diabetes” OR “T2DM” AND “glucose-lowering therapy” AND (“SGLT2 inhibitors” OR “GLP-1 receptor agonists” OR “DPP-4 inhibitors” OR “metformin”) AND (“cardiovascular mechanisms” OR “oxidative stress” OR “echocardiography” OR “cardiac MRI” OR “endothelial function” OR “biomarkers”).